Principal Investigator/Program Director (Last, First, Middle):
DORSEY, Jay Fitzgerald
BIOGRAPHICAL SKETCH
Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.
NAME
POSITION TITLE
Jay Fitzgerald Dorsey, MD, PhD
Assistant Professor of Radiation Oncology
eRA COMMONS USER NAME
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
INSTITUTION AND LOCATION
DEGREE
(if applicable)
YEAR(s)
University of Florida, Gainesville, FL
University of South Florida, Tampa, FL
University of South Florida, Tampa, FL
University of South Florida, Tampa, FL
University of South Florida, Tampa, FL
University of Pennsylvania, Philadelphia, PA
University of Pennsylvania, Philadelphia, PA
BSChE
MSChE
MD
PhD
Internship
Residency
Post-Doc
1992-95
1995-97
1997-03
1999-03
2003-04
2004-08
2005-07
FIELD OF STUDY
Chemical Engineering
Chemical Engineering
Medicine
Molecular Oncology
Medicine
Radiation Oncology
Radiation Biology
A. Positions and Honors.
Positions
06/94-08/94 Nuclear Engineering Intern, General Electric Nuclear Energy
08/95-12/97 Graduate Student, Department of Chemical Engineering
06/99-05/03 Doctoral Student, Laboratory of Jie Wu, Moffitt Cancer Center: Molecular
Oncology Program
07/03-06/04 Medical Intern, University of South Florida, Tampa General Hospital
07/04-06/08 B. Leonard Holman Pathway Radiation Oncology Resident, Hospital of the
University of Pennsylvania
07/05-03/07 Post-Doctoral Research Scientist, Laboratory of Wafik S. El-Deiry, Laboratory of
Molecular Oncology and Cell Cycle Regulation, Radiation Biology Program,
University of Pennsylvania
08/08-present Assistant Professor of Radiation Oncology, University of Pennsylvania School of
Medicine
1992-1995
1992-1994
1996, 1998
2001-03
2003
2003
2003
2004-2008
2005
2006
2007
2008
Honors
Florida Undergraduate Scholar Award
Florida Engineering Society Scholarship
Summer Research Fellowship, USF Office of Research and Graduate Affairs
USF College of Medicine Advancement Scholarship
Watson Clinic Award (for outstanding medical student research)
Moffitt Cancer Center Director’s Award
USF Outstanding Dissertation Prize
B. Leonard Holman Research Pathway, American Board of Radiology
ASTRO Young Investigator Award
ASCI/AAP Travel Award (Annual Joint Meeting)
Burroughs Wellcome Career Award for Medical Scientists
ASCO Foundation Young Investigator Award
PHS 398/2590 (Rev. 09/04)
Page
1
Biographical Sketch Format Page
Principal Investigator/Program Director (Last, First, Middle):
DORSEY, Jay Fitzgerald
B. Peer-Reviewed Publications.
1. Cunnick, JM, Dorsey, JF, Mei, L, and Wu, J. (1998) Reversible regulation of SHP-1 tyrosine
phosphatase activity by oxidation. Biochem Mol Biol Int 45(5):887-894.
2. Cunnick, JM, Dorsey, JF, Standley, T, Turkson, J, Kraker, AJ, Fry, DW, Jove, R, and Wu, J.
(1998) Role of tyrosine kinase activity of epidermal growth factor receptor in the
lysophosphatidic acid-stimulated MAP kinase pathway. J Biol Chem 273(23):14468-14475.
3. Cunnick, JM, Dorsey, JF, Munoz-Antonia, T, Mei, L, and Wu, J. (2000) Requirement of SHP-2
binding to Grb2-associated binder-1 for mitogen activated protein kinase activation in response
to lysophosphatidic acid-stimulated MAP kinase pathway. J Biol Chem 275(18):13842-13848.
4. Dorsey, JF, Jove, R, Kraker, AJ, and Wu, J. (2000) The pyrido[2,3-d]pyrimidine derivative
PD180970 inhibits Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells.
Cancer Res 60(12):3127-3131.
5. Huang, M, Dorsey, JF, Epling-Burnette, PK, Nimmanapalli, R, Landowski, TH, Mora, LB, Niu,
G, Sinibaldi, D, Bai, F, Kraker, A, Yu, H, Moscinski, L, Wei, S, Djeu, J, Dalton, WS, Bhalla, K,
Loughran, TP, Wu, J, and Jove, R. (2002) Inhibition of Bcr-Abl kinase activity by PD180970
blocks activation of Stat5 and growth of CML cells. Oncogene 21(57):8804-8816.
6. Dorsey, JF, Cunnick, JM, Lanehart, R, Bhalla, K, Kraker, AJ, Jove, R, and Wu, J. (2002)
Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis
induced by Bcr-Abl tyrosine kinase inhibitors. Leukemia 16(9):1589-1595.
7. Dorsey, JF, Cunnick, JM, Mane, SM, and Wu, J. (2002) Regulation of the Erk2-Elk1 signaling
pathway and megakaryocytic differentiation of Bcr-Abl + K562 leukemic cells by Gab2. Blood
99(4):1388-1397.
8. Wang S, Mintz A, Mochizuki K, Dorsey, JF, Ackermann JM, Alavi A, and El-Deiry WS. (2007)
Multimodality optical imaging and 18F-FDG uptake in wild-type p53-containing and p53-null
human colon tumor xenografts. Cancer Biol Ther 6(10): 1649-1653.
9. Matthew EM, Yen TJ, Dicker DT, Dorsey, JF, Yang W, Navaraj A, and El-Deiry WS. (2007)
Replication stress, defective S-phase checkpoint, and increased death in Plk2-deficient human
cancer cells. Cell Cycle 6(20): 2571-2578.
10. Plastaras, JP, Liu, Y, Kim, S-H, Dicker, DT, McDonough, J, Dorsey, JF, Flaherty, K, Smith, C,
and El-Deiry, WS. (2007) Cell cycle and schedule dependent anti-tumor effects of sorafenib
combined with radiation. Cancer Res 67(19): 9443-9454.
11. Yamaguchi, H, Woods, NT, Dorsey, JF, Takahashi, Y, Gjertsen, NR, Yeatman, T, Wu, J, and
Wang, HG. (2008) SRC directly phosphorylates BIF-1 and prevents its interaction with Bax and
the initiation of anoikis. J Biol Chem 283(27):19112-19118.
C. Research Support.
Ongoing
ASCO Young Investigator Award
7/01/08-6/30/09
American Society of Clinical Oncology (ASCO) Foundation
A Phase I Trial of the Protease Inhibitor Nelfinavir and Concurrent Radiation and Temozolomide
in Patients with WHO Grade IV Glioma
The goal of this project is to determine the maximally tolerated dose (MTD) and safety of
NELFINAVIR in combination with radiotherapy and Temozolomide in patients with WHO Grade IV
glioma.
PHS 398/2590 (Rev. 09/04)
Page
2
Continuation Format Page
Principal Investigator/Program Director (Last, First, Middle):
DORSEY, Jay Fitzgerald
Burroughs Wellcome Career Award for Medical Scientists (CAMS)
9/01/07-6/30/12
Burroughs Wellcome Fund
Role of novel p53 target genes in mediating transcriptional repression
The major goals of this project are to define the cellular and molecular mechanisms by which
mSin3B and Mad4 modulate radiation-induced transcription and examine the role of these
corepressors in p53-mediated tumor suppression in an in vivo orthotopic xenograft mouse model.
Completed
HPSD0609 (P.I.: Dorsey, J.F.)
7/01/06-6/30/08
Radiological Society of North American (RSNA)
Synergistic activity of taxol, radiation, and TRAIL in therapy of glioblastoma multiforme with
mutant p53 genes
The goal of this project is to determine the efficacy of paclitaxel, radiation, and TRAIL combination
therapy in a preclinical model of Glioblastoma Multiforme utilizing non-invasive in vivo multimodality imaging.
PHS 398/2590 (Rev. 09/04)
Page
3
Continuation Format Page